Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

Ellis, Rodney J.; Zhou, Hang; Kim, Edward Y.; Fu, Pingfu; Kaminsky, Deborah A.; Sodee, Bruce; Colussi, Valdir C.; Vance, W.; Spirnak, J. Patrick; Kim, Carolyn; Resnick, Martin I.

doi:10.1016/j.brachy.2006.11.002

Cited by 29 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One unknown remains; will LDR brachytherapy boost techniques allow for better biochemical disease free survival (bDFS)? Another study by Ellis et al that evaluated bDFS in patients treated with a boost technique guided by imaging concluded that their selective boost technique allowed for bDFS comparable to that reported in literature (4). Their results could, however, have been confounded by patient and treatment heterogeneity.…”

Section: Discussionmentioning

confidence: 90%

“…Many imaging methods and sextant biopsy are currently being investigated as methods to define involved areas to allow regional boost to the prostate (4,6,9,10). The superiority of imaging studies over biopsy alone for defining areas of involvement has never been demonstrated.…”

Section: Introductionmentioning

confidence: 98%

“…Thus, with the existence of a dose-response curve and evidence of increased recurrence in involved areas, increasing dosage to involved areas could be desirable. Such approaches are only beginning to be applied to prostate cancer treated with external beam radiation, high dose rate (HDR) brachytherapy and low dose rate (LDR) brachytherapy (4)(5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dose Escalation to the Dominant Intraprostatic Lesion Defined by Sextant Biopsy in a Permanent Prostate I-125 Implant: A Prospective Comparative Toxicity Analysis

Gaudet

Vigneault

Aubin

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dose Escalation to the Dominant Intraprostatic Lesion Defined by Sextant Biopsy in a Permanent Prostate I-125 Implant: A Prospective Comparative Toxicity Analysis

Gaudet

Vigneault

Aubin

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…MRI spectroscopy has been advocated to offer the ability to focus treatment on malignant sites, but no center has published data on truly focal therapy [34].…”

Section: Focal Brachytherapymentioning

confidence: 99%

Focal or Subtotal Therapy for Early Stage Prostate Cancer

Jones

2007

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Focal treatment for prostate cancer is highly intriguing, but poorly supported by the published literature. Further studies, preferably randomized controlled trials, are needed before this can be considered standard therapy. Focal treatment should be reserved for patients with focal disease. Even "clinically insignificant" synchronous tumors are malignant, and carry risk of progression if not treated with the index lesion. Whether these are likely to progress in this setting compared to those managed with active surveillance is unknown. The limited data regarding subtotal or focal cryotherapy suggest that patients properly evaluated for presence of satellite tumors have a low risk of having large unknown satellite tumors. The author requires office-based saturation biopsy prior to considering focal cryotherapy. Observation of prostatic intraepithelial neoplasia (PIN), atypical findings (ASAP), or cancer on the contralateral biopsy cores excludes the patient from consideration of subtotal therapy. MRI offers a potential additional ability to detect occult contralateral tumors. Younger men paradoxically seem to have greater interest in focal therapy while having a higher risk of future malignancy in the untreated areas based on the years of potential risk. However, no age cutoff is established. Without published data to support its use, lumpectomy or freezing only the focus where cancer is believed to exist, will remain limited. Hemispheric or subtotal treatment decreases the amount of untreated tissue. As a result, the local failure rate would be predicted to be lower but is unknown. When performing subtotal treatment, the author freezes almost the entire gland, sparing only the aspect adjacent to the contralateral neurovascular bundle, and has found this practice to be of highly limited utility based on the issues described. Biopsy should be performed following any treatment that fails to target the entire gland. A positive biopsy should be dealt with based on clinical factors as if the patient had not been treated, and a positive biopsy should not preclude active surveillance if deemed appropriate.

show abstract

“…(Adapted and reproduced permission of reference [115].) Anatomic localization, evaluation of therapeutic efficacy for pancreatic chemotherapy [180,[191][192][193] Parathyroid gland 99m Tc-sestamibi Anatomical localization [161,[194][195][196][197][198] Pheochromocytoma 123 I-metaiodobenzylguanidine Anatomical localization [189] Prostate cancer 111 In-capromab pendetide Attenuation correction, anatomical localization, monitoring brachytherapy [12,26,[199][200][201][202][203][204] Whole body (phantom study) Technetium-99m Attenuation correction, radioimmunotherapy dosimetry [226] …”

Section: Discussionmentioning

confidence: 99%

Technological Development and Advances in Single-Photon Emission Computed Tomography/Computed Tomography

Seo

Marì

Hasegawa

2008

Seminars in Nuclear Medicine

170

View full text Add to dashboard Cite

SPECT/CT has emerged over the past decade as a means of correlating anatomical information from CT with functional information from SPECT. The integration of SPECT and CT in a single imaging device facilitates anatomical localization of the radiopharmaceutical to differentiate physiological uptake from that associated with disease and patient-specific attenuation correction to improve the visual quality and quantitative accuracy of the SPECT image. The first clinically available SPECT/CT systems performed emission-transmission imaging using a dual-headed SPECT camera and a low-power x-ray CT sub-system. Newer SPECT/CT systems are available with high-power CT sub-systems suitable for detailed anatomical diagnosis, including CT coronary angiography and coronary calcification that can be correlated with myocardial perfusion measurements. The high-performance CT capabilities also offer the potential to improve compensation of partial volume errors for more accurate quantitation of radionuclide measurement of myocardial blood flow and other physiological processes and for radiation dosimetry for radionuclide therapy. In addition, new SPECT technologies are being developed that significantly improve the detection efficiency and spatial resolution for radionuclide imaging of small organs including the heart, brain, and breast, and therefore may provide new capabilities for SPECT/CT imaging in these important clinical applications.

show abstract

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

Cited by 29 publications

References 36 publications

Dose Escalation to the Dominant Intraprostatic Lesion Defined by Sextant Biopsy in a Permanent Prostate I-125 Implant: A Prospective Comparative Toxicity Analysis

Dose Escalation to the Dominant Intraprostatic Lesion Defined by Sextant Biopsy in a Permanent Prostate I-125 Implant: A Prospective Comparative Toxicity Analysis

Focal or Subtotal Therapy for Early Stage Prostate Cancer

Technological Development and Advances in Single-Photon Emission Computed Tomography/Computed Tomography

Contact Info

Product

Resources

About